- Home
- BRTX vs BLRX Comparison
BRTX vs BLRX Comparison
Compare BRTX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- BLRX
- Stock Information
- Founded
- BRTX 1997
- BLRX 2003
- Country
- BRTX United States
- BLRX Israel
- Employees
- BRTX N/A
- BLRX N/A
- Industry
- BRTX Managed Health Care
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- BLRX Health Care
- Exchange
- BRTX Nasdaq
- BLRX Nasdaq
- Market Cap
- BRTX 15.9M
- BLRX 17.3M
- IPO Year
- BRTX N/A
- BLRX 2011
- Fundamental
- Price
- BRTX $1.80
- BLRX $3.59
- Analyst Decision
- BRTX Strong Buy
- BLRX Strong Buy
- Analyst Count
- BRTX 1
- BLRX 2
- Target Price
- BRTX $18.00
- BLRX $220.00
- AVG Volume (30 Days)
- BRTX 812.7K
- BLRX 154.8K
- Earning Date
- BRTX 03-28-2025
- BLRX 03-25-2025
- Dividend Yield
- BRTX N/A
- BLRX N/A
- EPS Growth
- BRTX N/A
- BLRX N/A
- EPS
- BRTX N/A
- BLRX N/A
- Revenue
- BRTX $377,000.00
- BLRX $21,991,000.00
- Revenue This Year
- BRTX $482.76
- BLRX N/A
- Revenue Next Year
- BRTX $212.24
- BLRX N/A
- P/E Ratio
- BRTX N/A
- BLRX N/A
- Revenue Growth
- BRTX 189.55
- BLRX N/A
- 52 Week Low
- BRTX $1.03
- BLRX $3.20
- 52 Week High
- BRTX $2.55
- BLRX $57.60
- Technical
- Relative Strength Index (RSI)
- BRTX 37.55
- BLRX 36.94
- Support Level
- BRTX $2.26
- BLRX $3.26
- Resistance Level
- BRTX $2.38
- BLRX $4.17
- Average True Range (ATR)
- BRTX 0.22
- BLRX 0.28
- MACD
- BRTX -0.09
- BLRX 0.24
- Stochastic Oscillator
- BRTX 7.98
- BLRX 36.26
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.